US Map / New Jersey
State NJ

Clinical Trials in New Jersey

Recruiting clinical trials with at least one study location in New Jersey. Data updated daily from ClinicalTrials.gov.

Total Trials
231
Recruiting Now
231
← Back to US Map
Top Conditions in New Jersey
Breast Cancer (6)Cancer (6)Malignant Solid Neoplasm (5)Multiple Myeloma (4)Advanced Solid Tumors (4)Breast Neoplasms (3)Alzheimer Disease (3)Malignant Neoplasm (3)Lung Cancer (3)Acute Myeloid Leukemia (3)Psoriasis (3)Ovarian Cancer (3)
NCT06819007 Phase 3
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy ...
Condition
Ovarian Cancer
Enrollment
582 pts
Location
United States, Australia, Austria
Sponsor
Daiichi Sankyo
View Trial →
NCT06827236 Phase 1, Phase 2
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called...
Condition
Locally Advanced Breast Cancer
Enrollment
380 pts
Location
United States, Canada, China
Sponsor
BioNTech SE
View Trial →
NCT05633654 Phase 3
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic...
Condition
Triple Negative Breast Cancer
Enrollment
1,514 pts
Location
United States, Australia, France
Sponsor
Gilead Sciences
View Trial →
NCT03816345 Phase 1
Recruiting
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastati...
Condition
Autoimmune Disease
Enrollment
300 pts
Location
United States, Canada
Sponsor
National Cancer Institute (NCI
View Trial →
NCT07220967 Phase 4
Recruiting
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander...
Condition
Breast Cancer
Enrollment
392 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
View Trial →
NCT05394103 Phase 1, Phase 2
Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Condition
Advanced Cancer
Enrollment
130 pts
Location
United States, South Korea
Sponsor
Qurient Co., Ltd.
View Trial →
NCT06856577 Phase 3
Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants ...
Condition
Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment
284 pts
Location
United States
Sponsor
Adverum Biotechnologies, Inc.
View Trial →
NCT02743858 N/A
Recruiting
Lymphedema Surveillance Study
Condition
Breast Cancer
Enrollment
1,250 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
View Trial →
NCT03723928 N/A
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Re...
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Enrollment
739 pts
Location
United States, Guam, Puerto Rico
Sponsor
SWOG Cancer Research Network
View Trial →
NCT06995638 N/A
Recruiting
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitaskin...
Condition
Healthy Aging
Enrollment
130 pts
Location
United States
Sponsor
Rutgers, The State University
View Trial →
NCT06057935 Phase 2
Recruiting
A Study of Additional Chemotherapy After Surgery for People With Malignant Perit...
Condition
Malignant Peritoneal Mesothelioma
Enrollment
64 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
View Trial →
NCT06176950 N/A
Recruiting
History of Neonatology
Condition
Oral History
Enrollment
15 pts
Location
United States
Sponsor
Rutgers, The State University
View Trial →
NCT06819891 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (...
Condition
Moderately to Severely Active Crohns Disease
Enrollment
425 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
View Trial →
NCT05836987 Phase 3
Recruiting
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial F...
Condition
Atrial Fibrillation
Enrollment
5,350 pts
Location
United States
Sponsor
Johns Hopkins University
View Trial →
NCT06137014 Phase 1, Phase 2
Recruiting
Fortified Oral Rehydration Therapy for Pediatric Diarrhea
Condition
Acute Gastroenteritis
Enrollment
72 pts
Location
United States
Sponsor
Paul A Breslin
View Trial →
NCT05079282 Phase 1
Recruiting
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Condition
Relapsed or Refractory T Cell Lymphoma
Enrollment
217 pts
Location
United States
Sponsor
Ono Pharmaceutical Co. Ltd
View Trial →
NCT07001384 Phase 1
Recruiting
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Pos...
Condition
Anaplastic Lymphoma Kinase
Enrollment
30 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
View Trial →
NCT07184996 Phase 3
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Partic...
Condition
Ulcerative Colitis
Enrollment
980 pts
Location
United States, Canada, Japan
Sponsor
Sanofi
View Trial →
NCT06629259 Phase 2
Recruiting
Guanfacine for Alcohol Use Disorder (AUD)
Condition
Alcohol Use Disorder
Enrollment
200 pts
Location
United States
Sponsor
Indiana University
View Trial →
NCT05918861 Phase 3
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Rece...
Condition
Acute Coronary Syndrome
Enrollment
2,000 pts
Location
United States, Canada, Puerto Rico
Sponsor
DalCor Pharmaceuticals
View Trial →
NCT06188585 N/A
Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal U...
Condition
Acute Gastrointestinal Bleeding
Enrollment
278 pts
Location
United States, Canada, Denmark
Sponsor
Medtronic - MITG
View Trial →
NCT06225596 Phase 2, Phase 3
Recruiting
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial ...
Condition
Metastatic Urothelial Cancer
Enrollment
956 pts
Location
United States, Argentina, Australia
Sponsor
BicycleTx Limited
View Trial →
NCT03493425 Phase 2
Recruiting
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Thera...
Condition
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
Enrollment
82 pts
Location
United States
Sponsor
ECOG-ACRIN Cancer Research Gro
View Trial →
NCT03435796 Phase 2, Phase 3
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Condition
Neoplasms
Enrollment
1,541 pts
Location
United States, Australia, Austria
Sponsor
Celgene
View Trial →
NCT06541262 Phase 1, Phase 2
Recruiting
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory...
Condition
Neuroblastoma
Enrollment
104 pts
Location
United States, Canada
Sponsor
Milton S. Hershey Medical Cent
View Trial →
Page 5 of 10 — 231 trials total
← Prev Next →